Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Show more

Location: 55 Collins Street, Melbourne, VIC, 3000, Australia | Website: https://www.mesoblast.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.65B

52 Wk Range

$6.00 - $22.00

Previous Close

$12.88

Open

$13.10

Volume

318,020

Day Range

$13.10 - $13.64

Enterprise Value

1.587B

Cash

161.6M

Avg Qtr Burn

-12.49M

Insider Ownership

0.06%

Institutional Own.

2.69%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RYONCIL™ (Remestemcel-L) Details
Acute graft-versus host disease

Approved

Quarterly sales

REVASCOR® (Rexlemestrocel) Details
Pediatric Hypoplastic Left Heart Syndrome (HLHS)

BLA

Submission

REVASCOR® (Rexlemestrocel) Details
Ischemic CHF with reduced ejection fraction (HFrEF) and inflammation

BLA

Submission

Rexlemestrocel Details
Chronic lower back pain (CLBP)

Phase 3

Update

Remestemcel-L Details
Inflammatory bowel disease, Bowel disorder, Crohns disease

Failed

Discontinued

Failed

Discontinued